vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ESCO TECHNOLOGIES INC (ESE). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $284.0M, roughly 1.0× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 9.9%, a 86.4% gap on every dollar of revenue. On growth, ESCO TECHNOLOGIES INC posted the faster year-over-year revenue change (17.3% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 7.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
ACAD vs ESE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $289.7M |
| Net Profit | $273.6M | $28.7M |
| Gross Margin | 90.8% | 41.4% |
| Operating Margin | 6.1% | 13.2% |
| Net Margin | 96.3% | 9.9% |
| Revenue YoY | 9.4% | 17.3% |
| Net Profit YoY | 90.3% | 22.2% |
| EPS (diluted) | $1.61 | $1.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $289.7M | ||
| Q3 25 | $278.6M | $286.5M | ||
| Q2 25 | $264.6M | $296.3M | ||
| Q1 25 | $244.3M | $265.5M | ||
| Q4 24 | $259.6M | $247.0M | ||
| Q3 24 | $250.4M | $298.5M | ||
| Q2 24 | $242.0M | $260.8M | ||
| Q1 24 | $205.8M | $249.1M |
| Q4 25 | $273.6M | $28.7M | ||
| Q3 25 | $71.8M | $218.7M | ||
| Q2 25 | $26.7M | $26.1M | ||
| Q1 25 | $19.0M | $31.0M | ||
| Q4 24 | $143.7M | $23.5M | ||
| Q3 24 | $32.8M | $34.3M | ||
| Q2 24 | $33.4M | $29.2M | ||
| Q1 24 | $16.6M | $23.2M |
| Q4 25 | 90.8% | 41.4% | ||
| Q3 25 | 92.2% | 45.9% | ||
| Q2 25 | 92.2% | 41.2% | ||
| Q1 25 | 91.7% | 41.1% | ||
| Q4 24 | 91.6% | 39.8% | ||
| Q3 24 | 92.5% | 40.1% | ||
| Q2 24 | 92.5% | 39.6% | ||
| Q1 24 | 88.8% | 38.8% |
| Q4 25 | 6.1% | 13.2% | ||
| Q3 25 | 12.8% | 17.2% | ||
| Q2 25 | 12.2% | 11.2% | ||
| Q1 25 | 7.9% | 15.3% | ||
| Q4 24 | 59.1% | 11.4% | ||
| Q3 24 | 12.6% | 14.8% | ||
| Q2 24 | 12.6% | 14.3% | ||
| Q1 24 | 7.4% | 11.7% |
| Q4 25 | 96.3% | 9.9% | ||
| Q3 25 | 25.8% | 76.3% | ||
| Q2 25 | 10.1% | 8.8% | ||
| Q1 25 | 7.8% | 11.7% | ||
| Q4 24 | 55.4% | 9.5% | ||
| Q3 24 | 13.1% | 11.5% | ||
| Q2 24 | 13.8% | 11.2% | ||
| Q1 24 | 8.0% | 9.3% |
| Q4 25 | $1.61 | $1.11 | ||
| Q3 25 | $0.42 | $8.43 | ||
| Q2 25 | $0.16 | $1.01 | ||
| Q1 25 | $0.11 | $1.20 | ||
| Q4 24 | $0.86 | $0.91 | ||
| Q3 24 | $0.20 | $1.32 | ||
| Q2 24 | $0.20 | $1.13 | ||
| Q1 24 | $0.10 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $103.8M |
| Total DebtLower is stronger | — | $145.5M |
| Stockholders' EquityBook value | $1.2B | $1.6B |
| Total Assets | $1.6B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.09× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $103.8M | ||
| Q3 25 | $258.0M | $101.3M | ||
| Q2 25 | $253.6M | $78.7M | ||
| Q1 25 | $217.7M | $57.4M | ||
| Q4 24 | $319.6M | $71.3M | ||
| Q3 24 | $155.1M | $66.0M | ||
| Q2 24 | $177.1M | $63.0M | ||
| Q1 24 | $204.7M | $59.4M |
| Q4 25 | — | $145.5M | ||
| Q3 25 | — | $186.0M | ||
| Q2 25 | — | $525.0M | ||
| Q1 25 | — | $88.0M | ||
| Q4 24 | — | $112.0M | ||
| Q3 24 | — | $122.0M | ||
| Q2 24 | — | $173.0M | ||
| Q1 24 | — | $191.0M |
| Q4 25 | $1.2B | $1.6B | ||
| Q3 25 | $917.3M | $1.5B | ||
| Q2 25 | $822.4M | $1.3B | ||
| Q1 25 | $765.2M | $1.3B | ||
| Q4 24 | $732.8M | $1.2B | ||
| Q3 24 | $577.2M | $1.2B | ||
| Q2 24 | $516.7M | $1.2B | ||
| Q1 24 | $464.0M | $1.2B |
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $976.9M | $1.8B | ||
| Q2 24 | $914.1M | $1.8B | ||
| Q1 24 | $855.1M | $1.8B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $68.9M |
| Free Cash FlowOCF − Capex | — | $63.0M |
| FCF MarginFCF / Revenue | — | 21.7% |
| Capex IntensityCapex / Revenue | — | 2.0% |
| Cash ConversionOCF / Net Profit | -0.18× | 2.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $239.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $68.9M | ||
| Q3 25 | $74.3M | $109.9M | ||
| Q2 25 | $64.0M | $73.7M | ||
| Q1 25 | $20.3M | $24.1M | ||
| Q4 24 | $40.4M | $34.2M | ||
| Q3 24 | $63.2M | $72.1M | ||
| Q2 24 | $25.0M | $36.2M | ||
| Q1 24 | $29.1M | $10.5M |
| Q4 25 | — | $63.0M | ||
| Q3 25 | $73.9M | $97.8M | ||
| Q2 25 | — | $64.9M | ||
| Q1 25 | — | $14.0M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $63.2M | $60.9M | ||
| Q2 24 | — | $27.6M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | 21.7% | ||
| Q3 25 | 26.5% | 34.1% | ||
| Q2 25 | — | 21.9% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 25.2% | 20.4% | ||
| Q2 24 | — | 10.6% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | 0.1% | 4.2% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | 0.0% | 3.8% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | -0.18× | 2.40× | ||
| Q3 25 | 1.03× | 0.50× | ||
| Q2 25 | 2.40× | 2.83× | ||
| Q1 25 | 1.07× | 0.78× | ||
| Q4 24 | 0.28× | 1.46× | ||
| Q3 24 | 1.93× | 2.10× | ||
| Q2 24 | 0.75× | 1.24× | ||
| Q1 24 | 1.76× | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
